Although silicone-based and then collagen-based dermal fillers have been used since the 1940s to fill facial defects, it was the introduction of hyaluronic acid (HA) based dermal fillers that brought these treatments into the mainstream. They also have a more natural feel than collagen and offer reliable reversibility. They opened the door to non-surgical rejuvenation. Galderma will launch the new syringe and packaging for all restylane products during the fall and continues to seek opportunities in the market.
Dr. Dayan looks forward to new directions and products. The safety profile has been established with more than 3,000 clinical studies and many new indications are being evaluated and studies are being developed for areas such as tear ducts and temples, which I think will be exciting for providers and patients. Inga Hansen is the executive editor of MedeSthetics.
What began as a single filler intended for nasolabial folds and puppet lines has expanded to a whole family of Restylane products, each aimed at different areas of the face. RESTYLANE is the original non-animal stabilized hyaluronic acid filler with more than 25 years of achievements and more than 50 million treatments worldwide. The RESTYLANE product portfolio includes RESTYLANE, RESTYLANE LYFT, RESTYLANE KYSSE, RESTYLANE VOLYME, RESTYLANE DEFYNE, RESTYLANE REFYNE, RESTYLANE EYELIGHT and RESTYLANE SKINBOOSTERS.
